Quinn Opportunity Partners LLC Makes New $484,000 Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)

Quinn Opportunity Partners LLC bought a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 65,976 shares of the company's stock, valued at approximately $484,000.

A number of other hedge funds have also modified their holdings of the company. SBI Securities Co. Ltd. purchased a new stake in shares of Vir Biotechnology during the 4th quarter worth approximately $60,000. PNC Financial Services Group Inc. boosted its holdings in Vir Biotechnology by 31.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company's stock valued at $61,000 after acquiring an additional 1,999 shares during the period. KBC Group NV grew its position in Vir Biotechnology by 136.5% in the 4th quarter. KBC Group NV now owns 8,970 shares of the company's stock valued at $66,000 after acquiring an additional 5,177 shares during the last quarter. CIBC Asset Management Inc bought a new stake in shares of Vir Biotechnology during the fourth quarter worth $74,000. Finally, Virtu Financial LLC purchased a new stake in shares of Vir Biotechnology during the fourth quarter valued at $94,000. 65.32% of the stock is currently owned by institutional investors.

Vir Biotechnology Stock Performance

NASDAQ:VIR remained flat at $5.44 during midday trading on Thursday. 264,460 shares of the company traded hands, compared to its average volume of 1,333,832. Vir Biotechnology, Inc. has a one year low of $4.95 and a one year high of $14.45. The company's fifty day simple moving average is $7.41 and its 200 day simple moving average is $8.13. The company has a market capitalization of $746.06 million, a price-to-earnings ratio of -1.39 and a beta of 1.14.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, beating analysts' consensus estimates of ($0.85) by $0.09. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The business had revenue of $12.37 million during the quarter, compared to analyst estimates of $8.14 million. On average, sell-side analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on VIR shares. Barclays lifted their price objective on shares of Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a report on Friday, February 28th. HC Wainwright reissued a "buy" rating and issued a $110.00 price objective on shares of Vir Biotechnology in a research note on Friday, February 28th. Needham & Company LLC reaffirmed a "buy" rating and set a $19.00 target price on shares of Vir Biotechnology in a research report on Thursday, February 27th. Leerink Partners increased their price target on Vir Biotechnology from $18.00 to $20.00 and gave the stock an "outperform" rating in a research report on Monday, January 13th. Finally, JPMorgan Chase & Co. lifted their price objective on Vir Biotechnology from $10.00 to $14.00 and gave the company a "neutral" rating in a report on Thursday, January 9th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $35.67.

Insiders Place Their Bets

In other news, CEO Backer Marianne De sold 79,712 shares of the business's stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total transaction of $474,286.40. Following the completion of the sale, the chief executive officer now owns 769,505 shares of the company's stock, valued at $4,578,554.75. The trade was a 9.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director George A. Scangos sold 10,964 shares of Vir Biotechnology stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total value of $107,556.84. Following the completion of the sale, the director now directly owns 708,295 shares in the company, valued at $6,948,373.95. This represents a 1.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 99,611 shares of company stock worth $663,525. Company insiders own 15.60% of the company's stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).